A randomized clinical trial on the effects of bupropion and buprenorphine on the reduction of methamphetamine craving

ConclusionsThe results support the safety and effectiveness of buprenorphine and bupropion in the treatment of methamphetamine withdrawal craving. Administration of 8  mg of buprenorphine per day can be recommended for the treatment of methamphetamine withdrawal cravings. We should note that it is to be expected that craving decreases over time without any medication. So the conclusion may not be that bupropion and buprenorphine both lower the craving. As the b uprenorphine is superior to bupropion, only buprenorphine does so for sure.Trial registrationIranian Registry of Clinical Trials (IRCT) registration number:IRCT2015010320540N1. Date registered: April 10, 2015.
Source: Trials - Category: Research Source Type: clinical trials